Date: 2015-02-09
Type of information: Licensing agreement
Compound: sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (Grazax® in Europe and Grastek® in North America), and the adrenaline auto-injector, Jext®
Company: ALK Abello (Denmark) bioCSL (Australia)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: licensing
Action mechanism: immmunotherapy product. sublingual allergy immunotherapy tablet
Disease: house dust mite allergy, grass pollen allergy, allergic rhinitis
Details:
- • On February 9, 2015, ALK and bioCSL announced that they have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as Grazax® in Europe and Grastek® in North America), and its adrenaline auto-injector, Jext®. ALK will be responsible for product supply and bioCSL will undertake registration and commercialisation of the products. As part of the agreement, ALK will receive a minor upfront payment of an undisclosed amount, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia. ALK will sell products to bioCSL at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by bioCSL. The partnership with bioCSL advances ALK’s strategy of broadening its geographical presence through partnerships, acquisitions or by establishing its own affiliates.
Financial terms:
Latest news:
Is general: Yes
